GlobeNewswire by notified

LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants


LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants

  • Groundbreaking in vivo studies will be progressed to explore the impact of IMAN cell therapies in solid tumour and immunology models uniquely available at the Saeb-Parsy Lab at the University of Cambridge

London, 16 May 2024 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company about to start clinical trials for its first-in-class allogeneic innate cell therapy, today announces it has been awarded a grant of over one million pounds from Innovate UK, the UK’s innovation agency. The grant will enable LIfT to show for the first time, how its immunomodulatory alpha neutrophils (IMANs) recruit immune cells in vivo to attack tumours using a new type of translational humanised mouse model suitable for human neutrophils. The new in vivo model will enable LIfT to rapidly assess the potential of different, new, product variants, tumour types and combination therapies prior to putting them into path to the clinic, thereby accelerating the development of LIfT’s IMAN cell therapy pipeline for the treatment of solid tumours and auto-immune disease.

The Innovate UK grant will fund a unique, world-class industry-academia collaboration between LIfT Biosciences and the world-leading Saeb-Parsy Lab (SPL) at the University of Cambridge, with the aim of investigating the impact of LIfT’s IMAN cell therapies in solid tumour and immunology indications using the cutting-edge humanised in vivo model systems developed at SPL.

SPL has developed and optimized cutting-edge tumour-bearing humanised mice which are essential for true modelling of IMAN safety and efficacy. Data generated from this collaboration will be integral for the better understanding of the mechanism of action (MoA) of IMANs and its potential for combination approaches in solid tumours and immunology, enabling LIfT to investigate its immunomodulatory and cytotoxic mechanisms.

IMANs’ ability to modulate the hostile solid tumour microenvironment (TME) is fundamental to their MoA. Standard in vivo tumour models in immunodeficient mice lack the necessary human immune system components to investigate recipient immunomodulation, underplaying the effectiveness of cell therapy modalities by only assaying direct cytotoxicity. SPL's humanised models use xenografted patient-derived tumour material (PDX), which allows a closer approximation of tumour architecture and component subsets that comprise the solid TME, more closely representing the modelling of the TME as would be encountered during human clinical trials. Of particular interest is how IMANs recruit and activate T-Cells and NK cells, and work with monoclonal antibodies (mAbs) on the Antibody-Dependent Cellular Cytotoxicity (ADCC) pathway to deliver antitumor antibody efficacy through lethal trogocytosis.

Alex Blyth, Chief Executive Officer of LIfT BioSciences, commented:The awarding of this grant from Innovate UK, the UK’s innovation agency, is an exciting step that will help expedite our pipeline of new products and their combinations into the clinic and will improve outcomes through the foresight it provides. Current standard mouse models do not have the right chemokines and growth factors to support human neutrophils optimally. Tumour-bearing humanised mice that have been adapted to support human neutrophils are therefore very useful for more accurate modelling of the effects of neutrophils for early insights into what we might see in human trials. We will now conduct groundbreaking in vivo studies to explore the impact of IMAN cell therapies in solid tumour and immunology models uniquely available at the Saeb-Parsy Lab.”

Kourosh Saeb-Parsy, Professor of Transplantation at the Department of Surgery at University of Cambridge, commented:“LIfT’s IMANs have a unique multimodal mechanism of action which suggests they have the potential to overcome the limitations of current immunotherapies in solid tumours.  Our group has developed and optimized cutting-edge humanised in vivo solid tumour models which are particularly suited for investigation of therapeutics with immunomodulatory properties, such as IMANs.  We are very excited to be working with LIfT on this project and are grateful for this funding from Innovate UK.”

LIfT is developing its ground-breaking patented IMAN product as an allogeneic cell therapy for the treatment of solid tumours. IMANs have the capacity to directly kill tumour cells in an innate antigen-independent manner while recruiting and immunomodulating host immune effector cells such as T cells and NK cells, to give a durable response and long-lasting anti-tumour immunity. LIfT’s IMANs are generated using LIfT’s proprietary Neutrophil-based Leukocyte Infusion Therapy (N-LIfT) platform, with future iPSC-derived and gene engineered products in the pipeline.


About LIfT BioSciences

LIfT BioSciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs).

LIfT is working towards expanding LIfT's immunomodulatory therapy approach into other therapeutical areas such as immunology, neurology and antimicrobial resistance. LIfT is committed to delivering complete remission in high unmet need solid tumours before the decade is out. LIfT BioSciences was founded by Alex Blyth following the death of his mother to pancreatic cancer. See

Further information

Investors & Media:
Alex Blyth

ICR Consilium
Mary-Jane Elliott, Namrata Taak, Lindsey Neville
+44 (0)7718

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Udstedelse af RSU program18.5.2024 11:34:18 CEST | pressemeddelelse

I overensstemmelse med bemyndigelsen fra generalforsamlingen den 18. april 2024 har bestyrelsen i dag indført et incitamentsprogram for selskabets bestyrelse. Incitamentetprogrammet er designet og struktureret omkring konceptet med at fastholde medlemmer af bestyrelsen samtidig med at der skabes incitament til en positiv aktiekursudvikling og virksomhedens resultater til gavn for selskabets aktionærer. Incitamentsprogrammet inkluderer Restricted Share Units ("RSU'er"), som giver ret til at deltagerne tildeles et antal aktier svarende til antallet af optjente RSU'er mod betaling af udnyttelseskursen. Programmet er underlagt en række betingelser som deltagerne skal overholde og som betyder at selskabet maksimalt vil skulle udstede 2.025 aktier til kurs 1.056 DKK forudsat at alle betingelser overholdes samt at den enkelte vælger at udnytte sine RSUér. Den beregnede værdi af programmet til den samlede bestyrelse ved brug af Black & Scholes er opgjort til DKK 350.146. Vestingkursen er bereg

Constellation Brands Announces Updated Time of Presentation at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 202418.5.2024 01:05:50 CEST | Press release

VICTOR, N.Y., May 17, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announces an updated time that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a previously announced fireside chat at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 2024 in New York, NY. The presentation is scheduled to begin at 4:30 p.m. EDT and is expected to cover the company’s strategic business initiatives, financial metrics, and operating performance, as well as outlook for the future. A live, listen-only webcast of the presentation will be available on the company’s investor relations website at under the News&Events section. When the presentation begins, financial information discussed in the presentation, and a reconciliation of reported GAAP financial measures with comparable and other non- GAAP financial mea

DBV Technologies Announces Plan to Implement ADS Ratio Change17.5.2024 22:30:00 CEST | Press release

Châtillon, France, May 17, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one-half (1/2) of one (1) ordinary share to a new ADS Ratio of one (1) ADS to one (1) ordinary share (the “ADS Ratio Change”). The Company anticipates that the ADS Ratio Change will be effective on or about June 3rd, 2024 (the “Effective Date”). For the Company’s ADS holders, the change in the ADS Ratio will have the same effect as a one-for-two reverse ADS split and is intended to enable the Company to regain compliance with

Oculis updates share capital for its existing at-the-market offering program17.5.2024 22:30:00 CEST | Press release

ZUG, May 17, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01, issued out of existing capital band (Kapitalband), for an aggregate of 1,000,000 ordinary shares of the Company (the "New Shares"), recorded as treasury shares. The number of registered shares issued by the Company as per its Articles of Association is 46,443,700, of which 41.7 million shares are outstanding. The New Shares were issued following the Company and Leerink Partners LLC (”Leerink Partners”) entering into a sales agreement (the "Sales Agreement") with respect to an at-the-market offering program on May 8, 2024 under which the Company may offer and sell, from time to time at its sole discretion, ordinary shares of the Company having an aggregate offering price of up to $100 million through Leerink Partners as its sales agent. The Company is

Metasphere Labs Unveils Decentralized Identity System at Consensus 2024 and Announces Carbon Aware Routing Protocol17.5.2024 22:05:00 CEST | Press release

VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce its participation in Consensus 2024 alongside Bot Ventures Inc. (“Bot Ventures”), where they will unveil an early demonstration of their innovative decentralized identity and domain name system. This platform utilizes Bitcoin blockchain technology to enhance online security and trust through decentralized digital identity solutions. Parties interested in seeing a demonstration of the prototype can book a meeting at Metasphere's private suite by contacting Natasha Ingram at New Carbon Aware Routing Protocol Initiative In addition to the demonstration, the Company is excited to announce a pioneering initiative to develop a carbon aware routing protocol for computer networks and the Internet. This protocol will enable Internet Service Providers (ISPs) a

HiddenA line styled icon from Orion Icon Library.Eye